

# Emad A Rakha

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4793805/publications.pdf>

Version: 2024-02-01

428  
papers

28,096  
citations

11651

70  
h-index

7950

149  
g-index

445  
all docs

445  
docs citations

445  
times ranked

32111  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Specific cell differentiation in breast cancer: a basis for histological classification. <i>Journal of Clinical Pathology</i> , 2022, 75, 76-84.   | 2.0 | 12        |
| 2  | Spindle cell lesions of the breast: a diagnostic approach. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 127-145.   | 2.8 | 26        |
| 3  | Assessment of mitotic activity in breast cancer: revisited in the digital pathology era. <i>Journal of Clinical Pathology</i> , 2022, 75, 365-372.   | 2.0 | 18        |
| 4  | Nuclear morphology in breast lesions: refining its assessment to improve diagnostic concordance. <i>Histopathology</i> , 2022, 80, 515-528.  | 2.9 | 8         |
| 5  | Ecdysoneless Protein Regulates Viral and Cellular mRNA Splicing to Promote Cervical Oncogenesis. <i>Molecular Cancer Research</i> , 2022, 20, 305-318.   | 3.4 | 6         |
| 6  | Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 1-14.                                 | 2.5 | 6         |
| 7  | Intra-operative assessment of sentinel lymph nodes for breast cancer surgery: An update. <i>Surgical Oncology</i> , 2022, 40, 101678.  | 1.6 | 4         |
| 8  | Quantifying Lymphatic in Human Tissue Samples. <i>Methods in Molecular Biology</i> , 2022, 2441, 183-189.  | 0.9 | 0         |
| 9  | Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 529-539.  | 2.5 | 11        |
| 10 | Head to head: Do neuroendocrine tumours in the breast truly exist?. <i>Histopathology</i> , 2022, , .  | 2.9 | 5         |
| 11 | Prognostic significance of heat shock protein 90AA1 (HSP90 $\alpha$ ) in invasive breast cancer. <i>Journal of Clinical Pathology</i> , 2022, 75, 263-269.   | 2.0 | 1         |
| 12 | Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. <i>Clinical Cancer Research</i> , 2022, 28, 1323-1334. | 7.0 | 7         |
| 13 | Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer. <i>Scientific Reports</i> , 2022, 12, 2742.  | 3.3 | 13        |
| 14 | Applications and implications of whole-slide imaging in breast pathology. <i>Diagnostic Histopathology</i> , 2022, 28, 149-155.  | 0.4 | 0         |
| 15 | Potential quality pitfalls of digitalized whole slide image of breast pathology in routine practice. <i>Modern Pathology</i> , 2022, 35, 903-910.  | 5.5 | 8         |
| 16 | Hypoxia Drives Centrosome Amplification in Cancer Cells via HIF1 $\alpha$ -dependent Induction of Polo-Like Kinase 4. <i>Molecular Cancer Research</i> , 2022, 20, 596-606.  | 3.4 | 12        |
| 17 | Digital Technology in Diagnostic Breast Pathology and Immunohistochemistry. <i>Pathobiology</i> , 2022, 89, 334-342.   | 3.8 | 7         |
| 18 | Defining the area of mitoses counting in invasive breast cancer using whole slide image. <i>Modern Pathology</i> , 2022, 35, 739-748.  | 5.5 | 9         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Automated quality assessment of large digitised histology cohorts by artificial intelligence. Scientific Reports, 2022, 12, 5002.   | 3.3  | 19        |
| 20 | Standardization of the tumor-stroma ratio scoring method for breast cancer research. Breast Cancer Research and Treatment, 2022, 193, 545-553.  | 2.5  | 16        |
| 21 | Breast tumor microenvironment structures are associated with genomic features and clinical outcome. Nature Genetics, 2022, 54, 660-669.   | 21.4 | 88        |
| 22 | Upregulation of Cyclin B2 () in breast cancer contributes to the development of lymphovascular invasion.. American Journal of Cancer Research, 2022, 12, 469-489.   | 1.4  | 0         |
| 23 | Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer. Npj Breast Cancer, 2022, 8, 57.   | 5.2  | 11        |
| 24 | Lessons from a breast cell annotation competition series for school pupils. Scientific Reports, 2022, 12, 7792.   | 3.3  | 1         |
| 25 | The characteristics and clinical significance of atypical mitosis in breast cancer. Modern Pathology, 2022, 35, 1341-1348.  | 5.5  | 9         |
| 26 | Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ. Pathobiology, 2022, 89, 382-392.   | 3.8  | 1         |
| 27 | SlideGraph<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si3.svg"><mml:msup><mml:mrow /><mml:mo>+</mml:mo></mml:msup></mml:math>: Whole slide image level graphs to predict HER2 status in breast cancer. Medical Image Analysis, 2022, 80, 102486. | 11.6 | 39        |
| 28 | Assessment of Predictive Biomarkers in Breast Cancer: Challenges and Updates. Pathobiology, 2022, 89, 263-277.  | 3.8  | 7         |
| 29 | Current and future applications of artificial intelligence in pathology: a clinical perspective. Journal of Clinical Pathology, 2021, 74, 409-414.  | 2.0  | 57        |
| 30 | Digital pathology and artificial intelligence will be key to supporting clinical and academic cellular pathology through COVID-19 and future crises: the PathLAKE consortium perspective. Journal of Clinical Pathology, 2021, 74, 443-447.                           | 2.0  | 49        |
| 31 | New Advances in Molecular Breast Cancer Pathology. Seminars in Cancer Biology, 2021, 72, 102-113.   | 9.6  | 37        |
| 32 | Werner Syndrome Protein Expression in Breast Cancer. Clinical Breast Cancer, 2021, 21, 57-73.e7.  | 2.4  | 8         |
| 33 | Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer. British Journal of Cancer, 2021, 124, 494-505.                    | 6.4  | 62        |
| 34 | The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer. Breast Cancer Research and Treatment, 2021, 185, 293-305.   | 2.5  | 26        |
| 35 | Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer. Breast Cancer Research and Treatment, 2021, 185, 615-627.   | 2.5  | 11        |
| 36 | Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. Histopathology, 2021, 78, 759-771.   | 2.9  | 13        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | Centrosome amplification: a quantifiable cancer cell trait with prognostic value in solid malignancies. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 319-339.   | 5.9  | 22        |
| 38 | Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers. <i>Theranostics</i> , 2021, 11, 8350-8361.   | 10.0 | 10        |
| 39 | Clinicopathological and Functional Evaluation Reveal NBS1 as a Predictor of Platinum Resistance in Epithelial Ovarian Cancers. <i>Biomedicines</i> , 2021, 9, 56.   | 3.2  | 5         |
| 40 | Combined total internal reflection AF spectral-imaging and Raman spectroscopy for fast assessment of surgical margins during breast cancer surgery. <i>Biomedical Optics Express</i> , 2021, 12, 940.                         | 2.9  | 8         |
| 41 | Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. <i>Modern Pathology</i> , 2021, 34, 1271-1281.                     | 5.5  | 43        |
| 42 | Correlations of morphological features and surgical management with clinical outcome in a multicentre study of 241 phyllodes tumours of the breast. <i>Histopathology</i> , 2021, 78, 871-881.                                | 2.9  | 5         |
| 43 | Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio $\geq 2.0$ , HER2) Tj ETQq 1 0.784314 rg 5T | 0.1  | 1         |
| 44 | Molecular disruption of DNA polymerase $\beta$ for platinum sensitisation and synthetic lethality in epithelial ovarian cancers. <i>Oncogene</i> , 2021, 40, 2496-2508.   | 5.9  | 12        |
| 45 | RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 42.  | 5.0  | 11        |
| 46 | Age-Related Biology of Early-Stage Operable Breast Cancer and Its Impact on Clinical Outcome. <i>Cancers</i> , 2021, 13, 1417.  | 3.7  | 4         |
| 47 | FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers. <i>Cancers</i> , 2021, 13, 1866.  | 3.7  | 12        |
| 48 | PP1, PKA and DARPP-32 in breast cancer: A retrospective assessment of protein and mRNA expression. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 5015-5024.   | 3.6  | 11        |
| 49 | Artificial intelligence for advance requesting of immunohistochemistry in diagnostically uncertain prostate biopsies. <i>Modern Pathology</i> , 2021, 34, 1780-1794.  | 5.5  | 16        |
| 50 | Artificial intelligence grading of breast cancer: a promising method to refine prognostic classification for management precision. <i>Histopathology</i> , 2021, 79, 187-199.   | 2.9  | 13        |
| 51 | The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 53-63.   | 2.5  | 4         |
| 52 | Adenomyoepithelioma of the breast: a proposal for classification. <i>Histopathology</i> , 2021, 79, 465-479.  | 2.9  | 24        |
| 53 | The Mammalian Ecdysoneless Protein Interacts with RNA Helicase DDX39A To Regulate Nuclear mRNA Export. <i>Molecular and Cellular Biology</i> , 2021, 41, e0010321.  | 2.3  | 6         |
| 54 | Diagnostic concordance of phyllodes tumour of the breast. <i>Histopathology</i> , 2021, 79, 607-618.  | 2.9  | 6         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Determining breast cancer biomarker status and associated morphological features using deep learning. <i>Communications Medicine</i> , 2021, 1, .  | 4.2 | 53        |
| 56 | SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 317-331.                    | 2.5 | 5         |
| 57 | The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer. <i>Cancers</i> , 2021, 13, 3963.   | 3.7 | 8         |
| 58 | Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 621-630.   | 2.5 | 6         |
| 59 | The frequency and clinical significance of DNA polymerase beta (POLÎ²) expression in breast ductal carcinoma in situ (DCIS). <i>Breast Cancer Research and Treatment</i> , 2021, 190, 39-51.                 | 2.5 | 1         |
| 60 | Predicting the Economic Impact of the COVID-19 Pandemic in the United Kingdom Using Time-Series Mining. <i>Economies</i> , 2021, 9, 137.   | 2.5 | 13        |
| 61 | Visual assessment of mitotic figures in breast cancer: a comparative study between light microscopy and whole slide images. <i>Histopathology</i> , 2021, 79, 913-925.                                       | 2.9 | 12        |
| 62 | Assessment of proliferation in breast cancer: cell cycle or mitosis? An observational study. <i>Histopathology</i> , 2021, 79, 1087-1098.  | 2.9 | 11        |
| 63 | Flower lose, a cell fitness marker, predicts COVID-19 prognosis. <i>EMBO Molecular Medicine</i> , 2021, 13, e13714.  | 6.9 | 4         |
| 64 | The ITIM-Containing Receptor: Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) Modulates Immune Response and Confers Poor Prognosis in Invasive Breast Carcinoma. <i>Cancers</i> , 2021, 13, 80. | 3.7 | 12        |
| 65 | Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis. <i>Cancers</i> , 2021, 13, 5694.  | 3.7 | 41        |
| 66 | Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers. <i>Npj Breast Cancer</i> , 2021, 7, 143.   | 5.2 | 8         |
| 67 | Atypia in breast pathology: what pathologists need to know. <i>Pathology</i> , 2021, , .   | 0.6 | 7         |
| 68 | The intra-tumoural stroma in patients with breast cancer increases with age. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 37-45.   | 2.5 | 12        |
| 69 | The role of glutaminase in cancer. <i>Histopathology</i> , 2020, 76, 498-508.  | 2.9 | 101       |
| 70 | PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers. <i>Cancer Letters</i> , 2020, 469, 124-133.   | 7.2 | 22        |
| 71 | The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 79-90.   | 2.5 | 18        |
| 72 | Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ. <i>Journal of Clinical Pathology</i> , 2020, 73, 76-82.  | 2.0 | 31        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 73 | Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 557-564.  | 2.5  | 13        |
| 74 | Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 349-357.  | 2.5  | 18        |
| 75 | Immunohistochemical assessment of HRASQ61R mutations in breast adenomyoepitheliomas. <i>Histopathology</i> , 2020, 76, 865-874.  | 2.9  | 19        |
| 76 | Artificial intelligence in digital breast pathology: Techniques and applications. <i>Breast</i> , 2020, 49, 267-273.   | 2.2  | 117       |
| 77 | Prognostic significance of nucleolar assessment in invasive breast cancer. <i>Histopathology</i> , 2020, 76, 671-684.  | 2.9  | 14        |
| 78 | Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. <i>British Journal of Cancer</i> , 2020, 122, 94-101.  | 6.4  | 35        |
| 79 | The prognostic value of the tumor-stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer. <i>International Journal of Cancer</i> , 2020, 146, 2296-2304.  | 5.1  | 41        |
| 80 | Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity. <i>Modern Pathology</i> , 2020, 33, 1056-1064.  | 5.5  | 35        |
| 81 | Digital pathology for primary diagnosis of screen-detected breast lesions: experimental data, validation and experience from four centres. <i>Histopathology</i> , 2020, 76, 968-975.  | 2.9  | 19        |
| 82 | IL6/STAT3 Signaling Hijacks Estrogen Receptor ± Enhancers to Drive Breast Cancer Metastasis. <i>Cancer Cell</i> , 2020, 38, 412-423.e9.  | 16.8 | 145       |
| 83 | The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ. <i>British Journal of Cancer</i> , 2020, 123, 1513-1520.  | 6.4  | 4         |
| 84 | Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. <i>Breast Cancer Research</i> , 2020, 22, 85. | 5.0  | 31        |
| 85 | The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer. <i>British Journal of Cancer</i> , 2020, 123, 1543-1552.  | 6.4  | 33        |
| 86 | Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 541-551.  | 2.5  | 22        |
| 87 | Retrospective assessment of cyclin-dependent kinase 5 mRNA and protein expression and its association with patient survival in breast cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 6263-6271.   | 3.6  | 8         |
| 88 | The prognostic significance of ALDH1A1 expression in early invasive breast cancer. <i>Histopathology</i> , 2020, 77, 437-448.  | 2.9  | 25        |
| 89 | A novel prognostic two-gene signature for triple negative breast cancer. <i>Modern Pathology</i> , 2020, 33, 2208-2220.  | 5.5  | 22        |
| 90 | Histological clues to the diagnosis of metastasis to the breast from extramammary malignancies. <i>Histopathology</i> , 2020, 77, 303-313.   | 2.9  | 19        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer. BMC Cancer, 2020, 20, 425.  | 2.6 | 10        |
| 92  | The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes. Breast Cancer Research and Treatment, 2020, 182, 581-589.                                     | 2.5 | 9         |
| 93  | Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes. Npj Breast Cancer, 2020, 6, 20.  | 5.2 | 25        |
| 94  | Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer. Cancers, 2020, 12, 1549.                           | 3.7 | 7         |
| 95  | The prognostic significance of immune microenvironment in breast ductal carcinoma in situ. British Journal of Cancer, 2020, 122, 1496-1506.  | 6.4 | 26        |
| 96  | The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma. Npj Breast Cancer, 2020, 6, 9.  | 5.2 | 19        |
| 97  | The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer. Breast Cancer Research and Treatment, 2020, 181, 1-12.                                  | 2.5 | 12        |
| 98  | Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 1407.                      | 4.1 | 24        |
| 99  | Feasibility of integrated high-wavenumber Raman imaging and fingerprint Raman spectroscopy for fast margin assessment in breast cancer surgery. Journal of Raman Spectroscopy, 2020, 51, 1986-1995.            | 2.5 | 18        |
| 100 | Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype. Pathobiology, 2020, 87, 218-231.  | 3.8 | 28        |
| 101 | Visual histological assessment of morphological features reflects the underlying molecular profile in invasive breast cancer: a morphomolecular study. Histopathology, 2020, 77, 631-645.                      | 2.9 | 15        |
| 102 | A Quantitative Centrosomal Amplification Score Predicts Local Recurrence of Ductal Carcinoma <i>In Situ</i> . Clinical Cancer Research, 2020, 26, 2898-2907.   | 7.0 | 4         |
| 103 | Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers. Scientific Reports, 2020, 10, 3009.                               | 3.3 | 34        |
| 104 | Predicting Metastasis Risk in Pancreatic Neuroendocrine Tumors Using Deep Learning Image Analysis. Frontiers in Oncology, 2020, 10, 593211.  | 2.8 | 20        |
| 105 | Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. Breast Cancer Research and Treatment, 2020, 182, 267-282.  | 2.5 | 58        |
| 106 | PIK3CÎ expression by fibroblasts promotes triple-negative breast cancer progression. Journal of Clinical Investigation, 2020, 130, 3188-3204.  | 8.2 | 33        |
| 107 | XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097420. | 3.2 | 10        |
| 108 | RAD50 deficiency is a predictor of platinum sensitivity in sporadic epithelial ovarian cancers. Molecular Biomedicine, 2020, 1, 19.  | 4.4 | 8         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Tubular Carcinoma. Encyclopedia of Pathology, 2020, , 384-387.   | 0.0 | 0         |
| 110 | The role of PIP5K1 $\beta$ /pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1 $\beta$ inhibitor. Oncogene, 2019, 38, 375-389.                                   | 5.9 | 29        |
| 111 | Machine learning-based prediction of breast cancer growth rate in vivo. British Journal of Cancer, 2019, 121, 497-504.   | 6.4 | 9         |
| 112 | ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers. Cancers, 2019, 11, 1149.  | 3.7 | 9         |
| 113 | Surgical management of ductal carcinoma in situ of the breast: A large retrospective study from a single institution. Breast Journal, 2019, 25, 1143-1153.                                     | 1.0 | 7         |
| 114 | Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast. Histopathology, 2019, 75, 931-937.   | 2.9 | 16        |
| 115 | A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk. Breast Cancer Research, 2019, 21, 83.  | 5.0 | 39        |
| 116 | ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p53 Deficient Cancer Cells and Influence Platinum Sensitivity. Cells, 2019, 8, 1271.                                    | 4.1 | 12        |
| 117 | CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. Breast Cancer Research and Treatment, 2019, 178, 535-544.     | 2.5 | 36        |
| 118 | Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer. British Journal of Cancer, 2019, 121, 776-785.                                  | 6.4 | 10        |
| 119 | Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas. Npj Breast Cancer, 2019, 5, 6.  | 5.2 | 21        |
| 120 | The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer. Breast Cancer Research and Treatment, 2019, 175, 27-38.              | 2.5 | 28        |
| 121 | Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ. Modern Pathology, 2019, 32, 1460-1472.   | 5.5 | 23        |
| 122 | Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study. Modern Pathology, 2019, 32, 1473-1485.             | 5.5 | 11        |
| 123 | Metadherin: A Therapeutic Target in Multiple Cancers. Frontiers in Oncology, 2019, 9, 349.   | 2.8 | 55        |
| 124 | A key genomic subtype associated with lymphovascular invasion in invasive breast cancer. British Journal of Cancer, 2019, 120, 1129-1136.  | 6.4 | 25        |
| 125 | Combining clustering and classification ensembles: A novel pipeline to identify breast cancer profiles. Artificial Intelligence in Medicine, 2019, 97, 27-37.                                  | 6.5 | 30        |
| 126 | The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. British Journal of Cancer, 2019, 120, 1075-1082. | 6.4 | 27        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. <i>Journal of Pathology</i> , 2019, 248, 326-338.   | 4.5 | 21        |
| 128 | Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 63-73.  | 2.5 | 7         |
| 129 | ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers. <i>Gynecologic Oncology</i> , 2019, 153, 416-424.   | 1.4 | 26        |
| 130 | The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma <i>in situ</i> . <i>Histopathology</i> , 2019, 74, 1025-1035.  | 2.9 | 16        |
| 131 | SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment. <i>British Journal of Cancer</i> , 2019, 120, 728-745.  | 6.4 | 3         |
| 132 | Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 105-115.                       | 2.5 | 9         |
| 133 | The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts. <i>Modern Pathology</i> , 2019, 32, 967-976.   | 5.5 | 41        |
| 134 | Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expression. <i>Scientific Reports</i> , 2019, 9, 16987.  | 3.3 | 11        |
| 135 | Outcome of radial scar/complex sclerosing lesion associated with epithelial proliferations with atypia diagnosed on breast core biopsy: results from a multicentric UK-based study. <i>Journal of Clinical Pathology</i> , 2019, 72, 800-804.                               | 2.0 | 13        |
| 136 | Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 387-399.   | 2.5 | 53        |
| 137 | Connexin 43 is an independent predictor of patient outcome in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 93-102.  | 2.5 | 25        |
| 138 | Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma <i>in situ</i> . <i>Modern Pathology</i> , 2019, 32, 639-649.   | 5.5 | 19        |
| 139 | Glutamate dehydrogenase (GLUD1) expression in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 79-91.  | 2.5 | 32        |
| 140 | Breast Tumours Resembling the Tall Cell Variant of Thyroid Papillary Carcinoma: Are They Part of the Papillary Carcinoma Spectrum or a Distinct Entity?. <i>Pathobiology</i> , 2019, 86, 83-91.   | 3.8 | 7         |
| 141 | Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 93-102.  | 2.5 | 17        |
| 142 | Immune Infiltration in Invasive Lobular Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 768-776.  | 6.3 | 76        |
| 143 | Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program. <i>Cancer Research</i> , 2018, 78, 2524-2535.  | 0.9 | 35        |
| 144 | Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort. <i>Histopathology</i> , 2018, 73, 339-344. | 2.9 | 44        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer. <i>Histopathology</i> , 2018, 73, 545-558.                      | 2.9 | 15        |
| 146 | Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 525-533.                         | 2.5 | 12        |
| 147 | BQ323636.1, a Novel Splice Variant to <i>NCOR2</i> , as a Predictor for Tamoxifen-Resistant Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3681-3691.                                   | 7.0 | 23        |
| 148 | Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine. <i>Pathobiology</i> , 2018, 85, 23-34.   | 3.8 | 65        |
| 149 | Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 277-286. | 2.5 | 19        |
| 150 | IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 537-549.                                      | 4.2 | 67        |
| 151 | High nuclear MSK1 is associated with longer survival in breast cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 509-517.                                       | 2.5 | 12        |
| 152 | Breast cancer intratumour heterogeneity: current status and clinical implications. <i>Histopathology</i> , 2018, 73, 717-731.   | 2.9 | 50        |
| 153 | Diagnostic concordance of reporting lymphovascular invasion in breast cancer. <i>Journal of Clinical Pathology</i> , 2018, 71, 802-805.   | 2.0 | 17        |
| 154 | Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes. <i>British Journal of Cancer</i> , 2018, 118, 1142-1151.           | 6.4 | 9         |
| 155 | The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes. <i>British Journal of Cancer</i> , 2018, 118, 1115-1122.               | 6.4 | 43        |
| 156 | Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. <i>Modern Pathology</i> , 2018, 31, 1226-1236.   | 5.5 | 56        |
| 157 | Breast cancer histologic grading using digital microscopy: concordance and outcome association. <i>Journal of Clinical Pathology</i> , 2018, 71, 680-686.   | 2.0 | 35        |
| 158 | Checkpoint Kinase 1 Expression Predicts Poor Prognosis in Nigerian Breast Cancer Patients. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 79-90.  | 3.8 | 10        |
| 159 | MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer. <i>British Journal of Cancer</i> , 2018, 118, 258-265.   | 6.4 | 74        |
| 160 | Diagnostic challenges in papillary lesions of the breast. <i>Pathology</i> , 2018, 50, 100-110.   | 0.6 | 40        |
| 161 | Invasion in breast lesions: the role of the epithelial-stroma barrier. <i>Histopathology</i> , 2018, 72, 1075-1083.   | 2.9 | 25        |
| 162 | Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations. <i>Histopathology</i> , 2018, 72, 183-190.   | 2.9 | 60        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 163 | Panoptic Overview of Triple-Negative Breast Cancer in Nigeria: Current Challenges and Promising Global Initiatives. <i>Journal of Global Oncology</i> , 2018, 4, 1-20.  | 0.5  | 7         |
| 164 | Low expression of G protein-coupled oestrogen receptor 1 (GPER) is associated with adverse survival of breast cancer patients. <i>Oncotarget</i> , 2018, 9, 25946-25956.  | 1.8  | 34        |
| 165 | The effect of human placental chorionic villi derived mesenchymal stem cell on triple-negative breast cancer hallmarks. <i>PLoS ONE</i> , 2018, 13, e0207593.   | 2.5  | 12        |
| 166 | Prolyl-4-hydroxylase $\beta$ subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS). <i>British Journal of Cancer</i> , 2018, 119, 1518-1526.  | 6.4  | 32        |
| 167 | Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma <i>In Situ</i> Induces Synthetic Lethality and Chemoprevention. <i>Cancer Research</i> , 2018, 78, 6818-6827.                    | 0.9  | 26        |
| 168 | Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair. <i>BMC Cancer</i> , 2018, 18, 1027.                       | 2.6  | 3         |
| 169 | Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. <i>Nature Communications</i> , 2018, 9, 3533.  | 12.8 | 92        |
| 170 | Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance. <i>Histopathology</i> , 2018, 73, 887-896.   | 2.9  | 62        |
| 171 | Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ. <i>Modern Pathology</i> , 2018, 31, 1807-1815.   | 5.5  | 23        |
| 172 | Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion. <i>Modern Pathology</i> , 2018, 31, 1675-1682.   | 5.5  | 13        |
| 173 | Intra-operative spectroscopic assessment of surgical margins during breast conserving surgery. <i>Breast Cancer Research</i> , 2018, 20, 69.  | 5.0  | 77        |
| 174 | Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 61-68.                                      | 2.5  | 10        |
| 175 | Eighth Edition Cancer Staging Manual of Breast Cancer by the American Joint Committee on Cancer: are the new changes to improve staging or a treatment decision tool?. <i>Journal of Clinical Pathology</i> , 2018, 71, 1028-1029.  | 2.0  | 6         |
| 176 | Impact of breast cancer grade discordance on prediction of outcome. <i>Histopathology</i> , 2018, 73, 904-915.  | 2.9  | 24        |
| 177 | Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. <i>Nature Communications</i> , 2018, 9, 1816.   | 12.8 | 105       |
| 178 | The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours. <i>Breast Cancer Research</i> , 2018, 20, 21.                   | 5.0  | 85        |
| 179 | Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape. <i>Breast Cancer Research</i> , 2018, 20, 39.  | 5.0  | 38        |
| 180 | A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. <i>Modern Pathology</i> , 2018, 31, 1770-1786. | 5.5  | 739       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 181 | Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1. <i>Clinical Cancer Research</i> , 2018, 24, 4566-4578.   | 7.0 | 31        |
| 182 | The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response. <i>Oncotarget</i> , 2018, 9, 29508-29524.  | 1.8 | 10        |
| 183 | Intra-operative Assessment of Excision margins During Breast Conserving Surgery by Integrated Raman Microscopy and Auto-fluorescence Imaging. , 2018, , .  |     | 0         |
| 184 | Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications. <i>Pathology Research and Practice</i> , 2017, 213, 27-33.        | 2.3 | 5         |
| 185 | Current topics in breast pathology: expert perspectives. <i>Pathology</i> , 2017, 49, 109-110.   | 0.6 | 0         |
| 186 | Amplified centrosomes and mitotic index display poor concordance between patient tumors and cultured cancer cells. <i>Scientific Reports</i> , 2017, 7, 43984.   | 3.3 | 20        |
| 187 | Androgen dependent mechanisms of pro-angiogenic networks in placental and tumor development. <i>Placenta</i> , 2017, 56, 79-85.  | 1.5 | 8         |
| 188 | Prognostic stratification of oestrogen receptorâ€positive <sc>HER</sc>2â€negative lymph nodeâ€negative class of breast cancer. <i>Histopathology</i> , 2017, 70, 622-631.  | 2.9 | 30        |
| 189 | Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers. <i>Cancer Immunology Research</i> , 2017, 5, 292-299.  | 3.4 | 56        |
| 190 | Review of the national external quality assessment (EQA) scheme for breast pathology in the UK. <i>Journal of Clinical Pathology</i> , 2017, 70, 51-57.  | 2.0 | 36        |
| 191 | Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 341-348.                                  | 2.5 | 44        |
| 192 | Phenotypic characterisation of breast cancer: the role of CDC42. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 317-325.   | 2.5 | 22        |
| 193 | Chemokine (Câ€C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 105-114. | 3.0 | 9         |
| 194 | Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma <i>in situ</i>. <i>Histopathology</i> , 2017, 71, 258-268.   | 2.9 | 58        |
| 195 | Immunoprofile of metaplastic carcinomas of the breast. <i>Histopathology</i> , 2017, 70, 975-985.  | 2.9 | 57        |
| 196 | DNA damage repair in breast cancer and its therapeutic implications. <i>Pathology</i> , 2017, 49, 156-165.   | 0.6 | 47        |
| 197 | Molecular classification of breast cancer: what the pathologist needs to know. <i>Pathology</i> , 2017, 49, 111-119.   | 0.6 | 83        |
| 198 | Reply to Rosen. <i>Modern Pathology</i> , 2017, 30, 1505-1506.   | 5.5 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 199 | Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer. <i>British Journal of Cancer</i> , 2017, 117, 1176-1184.  | 6.4 | 16        |
| 200 | Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers. <i>British Journal of Cancer</i> , 2017, 117, 826-834.  | 6.4 | 14        |
| 201 | The Spectrum of Triple-Negative Breast Disease. <i>American Journal of Pathology</i> , 2017, 187, 2139-2151.  | 3.8 | 118       |
| 202 | An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. <i>Breast Cancer Research</i> , 2017, 19, 58.  | 5.0 | 161       |
| 203 | Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2017, 22, 357-368.  | 4.9 | 124       |
| 204 | Breast conservation in ductal carcinoma <i>in situ</i> (DCIS): what defines optimal margins?. <i>Histopathology</i> , 2017, 70, 681-692.  | 2.9 | 13        |
| 205 | Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 239-250.  | 4.1 | 17        |
| 206 | Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance Scheme. <i>Histopathology</i> , 2017, 70, 632-642.                  | 2.9 | 22        |
| 207 | Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. <i>Modern Pathology</i> , 2017, 30, 69-84. | 5.5 | 48        |
| 208 | Further evidence to support bimodality of oestrogen receptor expression in breast cancer. <i>Histopathology</i> , 2017, 70, 456-465.  | 2.9 | 12        |
| 209 | Grading of Invasive Carcinoma. , 2017, , 87-95.   |     | 1         |
| 210 | Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: Critical review. <i>Breast</i> , 2017, 35, 151-156.   | 2.2 | 24        |
| 211 | Papillary Carcinomas. , 2017, , 137-152.  |     | 1         |
| 212 | Metaplastic Breast Carcinomas. , 2017, , 153-166.   |     | 0         |
| 213 | Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance. <i>Frontiers in Oncology</i> , 2016, 6, 145.   | 2.8 | 24        |
| 214 | Papillary carcinoma of the breast: diagnostic agreement and management implications. <i>Histopathology</i> , 2016, 69, 862-870.   | 2.9 | 25        |
| 215 | Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profile. <i>Histopathology</i> , 2016, 68, 1030-1039.   | 2.9 | 31        |
| 216 | Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations. <i>Journal of Pathology</i> , 2016, 238, 677-688.              | 4.5 | 52        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 217 | Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer. Breast Cancer Research and Treatment, 2016, 158, 287-295.  | 2.5 | 19        |
| 218 | Pleomorphic adenoma-like tumour of the breast. Histopathology, 2016, 68, 405-410.   | 2.9 | 15        |
| 219 | Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?. Histopathology, 2016, 69, 20-24. | 2.9 | 8         |
| 220 | Novel Immunohistochemical Based Biomarkers in Breast Cancer. , 2016, , 99-119.  |     | 0         |
| 221 | Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer. Breast Cancer Research and Treatment, 2016, 157, 65-75.   | 2.5 | 24        |
| 222 | Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series. Journal of Pathology: Clinical Research, 2016, 2, 32-40.                                   | 3.0 | 36        |
| 223 | An approach to the diagnosis of spindle cell lesions of the breast. Histopathology, 2016, 68, 33-44.  | 2.9 | 50        |
| 224 | Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein. Breast Cancer Research and Treatment, 2016, 159, 41-53.   | 2.5 | 37        |
| 225 | Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. Histopathology, 2016, 68, 45-56.                                       | 2.9 | 37        |
| 226 | Phyllodes tumours of the breast: a consensus review. Histopathology, 2016, 68, 5-21.  | 2.9 | 329       |
| 227 | Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis. Breast Cancer Research and Treatment, 2016, 159, 215-227.                          | 2.5 | 81        |
| 228 | Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers. Breast Cancer Research and Treatment, 2016, 159, 457-467.  | 2.5 | 22        |
| 229 | Invasive Lobular Carcinoma Mimicking Papillary Carcinoma: A Report of Three Cases. Pathobiology, 2016, 83, 221-227.   | 3.8 | 14        |
| 230 | ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC. Breast Cancer Research, 2016, 18, 113.   | 5.0 | 10        |
| 231 | <sc>RECQL4</sc> helicase has oncogenic potential in sporadic breast cancers. Journal of Pathology, 2016, 238, 495-501.  | 4.5 | 43        |
| 232 | Construction of tissue microarrays from core needle biopsies – a systematic literature review. Histopathology, 2016, 68, 323-332.   | 2.9 | 18        |
| 233 | Imaging overview of metaplastic carcinomas of the breast: a large study of 71 cases. British Journal of Radiology, 2016, 89, 20140644.  | 2.2 | 28        |
| 234 | Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 5929-5938.                                     | 7.0 | 66        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 235 | Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 493-502. | 2.8 | 30        |
| 236 | Clinical utility of reverse phase protein array for molecular classification of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 25-35.   | 2.5 | 16        |
| 237 | Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radioresistance in breast cancer. <i>Molecular Oncology</i> , 2016, 10, 213-223.   | 4.6 | 33        |
| 238 | The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 9-20.  | 2.5 | 29        |
| 239 | MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. <i>British Journal of Cancer</i> , 2016, 114, 917-928.  | 6.4 | 91        |
| 240 | Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers. <i>Carcinogenesis</i> , 2016, 37, 63-71.  | 2.8 | 31        |
| 241 | Morphogenesis of the papillary lesions of the breast: phenotypic observation. <i>Journal of Clinical Pathology</i> , 2016, 69, 64-69.  | 2.0 | 7         |
| 242 | Raman spectral histopathology of breast cancer recession margins. , 2016, , .  |     | 0         |
| 243 | Potential of a novel technique for constructing tissue microarrays from core needle biopsy as seen in older women with primary breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23283-e23283.  | 1.6 | 0         |
| 244 | Multi-institutional study of triple negative breast cancer stratification by a metric that quantifies cell cycling kinetics.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1091-1091.   | 1.6 | 0         |
| 245 | Identifying likely metastatic sites for triple negative breast cancers using immunohistochemical biomarkers.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1092-1092.   | 1.6 | 0         |
| 246 | A combined HER3-EGFR score in triple-negative breast cancer: racial differences.. <i>Journal of Clinical Oncology</i> , 2016, 34, e12560-e12560.   | 1.6 | 0         |
| 247 | A multi-institutional study of racial differences in androgen receptor status among triple-negative breast cancers.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1089-1089.  | 1.6 | 1         |
| 248 | The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. <i>Journal of Pathology</i> , 2015, 237, 166-178.  | 4.5 | 53        |
| 249 | Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. <i>Histopathology</i> , 2015, 67, 529-537.  | 2.9 | 37        |
| 250 | A Case-Controlled Study of the Oncologic Safety of Fat Grafting. <i>Plastic and Reconstructive Surgery</i> , 2015, 135, 1263-1275.   | 1.4 | 108       |
| 251 | High-grade encapsulated papillary carcinoma of the breast: an under-recognized entity. <i>Histopathology</i> , 2015, 66, 740-746.  | 2.9 | 51        |
| 252 | Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. <i>British Journal of Cancer</i> , 2015, 112, 1613-1615.  | 6.4 | 35        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 253 | Molecular-Based Diagnostic, Prognostic and Predictive Tests in Breast Cancer. Molecular Pathology Library, 2015, , 177-195.  | 0.1 | 1         |
| 254 | Molecular Pathology of Breast Cancer Metastasis. Molecular Pathology Library, 2015, , 271-289.   | 0.1 | 1         |
| 255 | Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Research, 2015, 17, 59.                  | 5.0 | 61        |
| 256 | Molecular Mechanisms Underlying Lymphovascular Invasion in Invasive Breast Cancer. Pathobiology, 2015, 82, 113-123.  | 3.8 | 59        |
| 257 | Breast Neoplasms with Dermal Analogue Differentiation (Mammary Cylindroma): Report of 3 Cases and a Proposal for a New Terminology. Pathobiology, 2015, 82, 172-178.   | 3.8 | 6         |
| 258 | A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. Molecular Oncology, 2015, 9, 115-127.   | 4.6 | 38        |
| 259 | Macroscopic handling and reporting of breast cancer specimens pre- and post- adjuvant chemotherapy treatment: review of pathological issues and suggested approaches. Histopathology, 2015, 67, 279-293.             | 2.9 | 26        |
| 260 | Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer. Molecular Cancer Therapeutics, 2015, 14, 1057-1065.                       | 4.1 | 42        |
| 261 | Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response. British Journal of Cancer, 2015, 112, 901-911.  | 6.4 | 35        |
| 262 | Updated UK Recommendations for HER2 assessment in breast cancer. Journal of Clinical Pathology, 2015, 68, 93-99.   | 2.0 | 203       |
| 263 | KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer. British Journal of Cancer, 2015, 112, 1929-1937.                                    | 6.4 | 55        |
| 264 | Untangling the ATR-CHK1 network for prognostication, prediction and therapeutic target validation in breast cancer. Molecular Oncology, 2015, 9, 569-585.  | 4.6 | 75        |
| 265 | Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer. Breast Cancer Research and Treatment, 2015, 150, 511-522.                                       | 2.5 | 26        |
| 266 | Biological and clinical significance of PARP1 protein expression in breast cancer. Breast Cancer Research and Treatment, 2015, 149, 353-362.   | 2.5 | 66        |
| 267 | DNA damage response markers are differentially expressed in BRCA-mutated breast cancers. Breast Cancer Research and Treatment, 2015, 150, 81-90.   | 2.5 | 40        |
| 268 | The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways. Breast Cancer Research and Treatment, 2015, 150, 91-103.                                  | 2.5 | 10        |
| 269 | Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification. Breast Cancer Research and Treatment, 2015, 151, 325-333. | 2.5 | 21        |
| 270 | Brief Fixation and Hormone Receptor Expression in Breast Cancer. American Journal of Surgical Pathology, 2015, 39, 425.  | 3.7 | 0         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 271 | Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer. Breast Cancer Research and Treatment, 2015, 150, 335-346.  | 2.5 | 68        |
| 272 | Molecular Pathology of Precancerous Lesions of the Breast. Molecular Pathology Library, 2015, , 51-62.   | 0.1 | 1         |
| 273 | Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators. European Journal of Cancer, 2015, 51, 1897-1903.   | 2.8 | 10        |
| 274 | National Guidelines and Level of Evidence: Comments on Some of the New Recommendations in the American Society of Clinical Oncology and the College of American Pathologists Human Epidermal Growth Factor Receptor 2 Guidelines for Breast Cancer. Journal of Clinical Oncology, 2015, 33, 1301-1302. | 1.6 | 35        |
| 275 | Molecular Classification of Breast Cancer. Molecular Pathology Library, 2015, , 137-155.   | 0.1 | 0         |
| 276 | Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. British Journal of Cancer, 2015, 112, 283-289.   | 6.4 | 93        |
| 277 | Targeting BRCA1/BER deficient breast cancer by ATM or DNA/CHKcs blockade either alone or in combination with cisplatin for personalized therapy. Molecular Oncology, 2015, 9, 204-217.   | 4.6 | 72        |
| 278 | FKBPL: a marker of good prognosis in breast cancer. Oncotarget, 2015, 6, 12209-12223.  | 1.8 | 13        |
| 279 | DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers. Oncotarget, 2015, 6, 21964-21978.   | 1.8 | 19        |
| 280 | The pioneer factor PBX1 is a novel driver of metastatic progression in ER±-positive breast cancer. Oncotarget, 2015, 6, 21878-21891.   | 1.8 | 45        |
| 281 | Towards intra-operative diagnosis of tumours during breast conserving surgery by selective-sampling Raman micro-spectroscopy. Physics in Medicine and Biology, 2014, 59, 6141-6152.  | 3.0 | 77        |
| 282 | PIAS1 expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women. Journal of Clinical Pathology, 2014, 67, 301-306.  | 2.0 | 10        |
| 283 | Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer. British Journal of Cancer, 2014, 110, 1688-1697.   | 6.4 | 84        |
| 284 | Clinicopathological Significance of ATM-Chk2 Expression in Sporadic Breast Cancers: a Comprehensive Analysis in Large Cohorts. Neoplasia, 2014, 16, 982-991.   | 5.3 | 37        |
| 285 | Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Annals of Oncology, 2014, 25, 1536-1543.   | 1.2 | 610       |
| 286 | Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer. BMC Cancer, 2014, 14, 908.   | 2.6 | 42        |
| 287 | Low calpain-9 is associated with adverse disease-specific survival following endocrine therapy in breast cancer. BMC Cancer, 2014, 14, 995.  | 2.6 | 19        |
| 288 | Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay. Breast Cancer Research and Treatment, 2014, 144, 273-285.  | 2.5 | 15        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 289 | SUMOylation proteins in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 519-530.   | 2.5  | 29        |
| 290 | The updated <sc>ASCO</sc>/<sc>CAP</sc> guideline recommendations for <sc>HER</sc>2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice. <i>Histopathology</i> , 2014, 64, 609-615. | 2.9  | 68        |
| 291 | Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 339-348.   | 2.5  | 55        |
| 292 | Updated guideline recommendations for HER2 testing. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 8-9.   | 27.6 | 13        |
| 293 | Câ€Met in invasive breast cancer. <i>Cancer</i> , 2014, 120, 163-171.  | 4.1  | 43        |
| 294 | Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 309-320.                      | 2.5  | 12        |
| 295 | ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 25-37.   | 2.5  | 17        |
| 296 | HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 33-44.  | 2.5  | 30        |
| 297 | Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 317-330.   | 2.5  | 10        |
| 298 | Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy. <i>Oncotarget</i> , 2014, 5, 12936-12949.   | 1.8  | 51        |
| 299 | Pathology and biology of breast cancer. , 2014, , 20-43.   |      | 0         |
| 300 | Predicting chemotherapy response in invasive breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1084-1084.  | 1.6  | 0         |
| 301 | Molecular profiling of breast cancer in Nigerian women identifies an altered p53 pathway as a major mechanism underlying its poor prognosis compared with British counterpart. <i>Malaysian Journal of Pathology</i> , 2014, 36, 3-17.           | 0.2  | 10        |
| 302 | Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers. <i>British Journal of Cancer</i> , 2013, 109, 1886-1894.   | 6.4  | 40        |
| 303 | Pitfalls in outcome prediction of breast cancer: TableÂ1. <i>Journal of Clinical Pathology</i> , 2013, 66, 458-464.  | 2.0  | 32        |
| 304 | Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R92.   | 5.0  | 320       |
| 305 | The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 307-316.   | 2.5  | 40        |
| 306 | Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 301-310.   | 2.5  | 56        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 307 | Authors' reply: combining two antibodies to define <i>E-cadherin</i> loss of expression in non-lobular breast carcinomas: when less is more. <i>Histopathology</i> , 2013, 63, 440-443.                    | 2.9 | 0         |
| 308 | Outcome of pure mucocoele-like lesions diagnosed on breast core biopsy. <i>Histopathology</i> , 2013, 62, 894-898.   | 2.9 | 47        |
| 309 | Breast pathology today: morphology and molecules. <i>Journal of Clinical Pathology</i> , 2013, 66, 457-457.  | 2.0 | 1         |
| 310 | Targeting XRCC1 Deficiency in Breast Cancer for Personalized Therapy. <i>Cancer Research</i> , 2013, 73, 1621-1634.  | 0.9 | 88        |
| 311 | Lack of expression of the proteins GMPR2 and PPAR $\alpha$ are associated with the basal phenotype and patient outcome in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 127-137. | 2.5 | 18        |
| 312 | The microRNA maturation regulator Drosha is an independent predictor of outcome in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 139-153.                               | 2.5 | 18        |
| 313 | Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 721-731.       | 2.5 | 15        |
| 314 | Characteristics of basal cytokeratin expression in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 23-37.  | 2.5 | 32        |
| 315 | Further evidence that <i>E-cadherin</i> is not a tumour suppressor gene in invasive ductal carcinoma of the breast: an immunohistochemical study. <i>Histopathology</i> , 2013, 62, 695-701.               | 2.9 | 25        |
| 316 | Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours. <i>Breast</i> , 2013, 22, 13-18.                    | 2.2 | 52        |
| 317 | Pleomorphic lobular carcinoma of the breast: is it a prognostically significant pathological subtype independent of histological grade?. <i>Modern Pathology</i> , 2013, 26, 496-501.                      | 5.5 | 41        |
| 318 | Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women. <i>ISRN Oncology</i> , 2013, 2013, 1-8.                                     | 2.1 | 15        |
| 319 | Lobular Neoplasia of the Breast Revisited With Emphasis on the Role of E-Cadherin Immunohistochemistry. <i>American Journal of Surgical Pathology</i> , 2013, 37, e1-e11.                                  | 3.7 | 137       |
| 320 | Histological risk factors, prognostic indicators and staging. , 2013, , 236-249.   |     | 0         |
| 321 | Abstract B120: Ada3, a component of ATAC complex is involved in regulation of the Genomic stability, DNA repair process and breast cancer. , 2013, , .   |     | 0         |
| 322 | Encapsulated papillary carcinoma of the breast: a study of invasion associated markers. <i>Journal of Clinical Pathology</i> , 2012, 65, 710-714.  | 2.0 | 41        |
| 323 | Efficacy of an incident-reporting system in cellular pathology: a practical experience. <i>Journal of Clinical Pathology</i> , 2012, 65, 643-648.  | 2.0 | 5         |
| 324 | Infiltrative epitheliosis of the breast. <i>Journal of Clinical Pathology</i> , 2012, 65, 766-768.   | 2.0 | 9         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 325 | The prognostic significance of early stage lymph node positivity in operable invasive breast carcinoma: number or stage. <i>Journal of Clinical Pathology</i> , 2012, 65, 624-630.  | 2.0  | 10        |
| 326 | Integrating Breast Cancer Genetics into Clinical Practice. <i>Women's Health</i> , 2012, 8, 99-112.   | 1.5  | 4         |
| 327 | PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. <i>British Journal of Cancer</i> , 2012, 107, 800-807.   | 6.4  | 163       |
| 328 | The value of examination of multiple levels of mammary needle core biopsy specimens taken for investigation of lesions other than calcification. <i>Journal of Clinical Pathology</i> , 2012, 65, 1097-1099.                  | 2.0  | 8         |
| 329 | Low Estrogen Receptor Positive Breast Cancer: The Impact of Tissue Sampling, Choice of Antibody, and Molecular Subtyping. <i>Journal of Clinical Oncology</i> , 2012, 30, 2929-2930.  | 1.6  | 16        |
| 330 | Clinical Outcome of Atypical Endometrial Hyperplasia Diagnosed on an Endometrial Biopsy. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1683-1690.   | 3.7  | 69        |
| 331 | Loss of Dicer expression is associated with breast cancer progression and recurrence. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 403-413.   | 2.5  | 77        |
| 332 | Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 555-569.  | 2.5  | 47        |
| 333 | TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 419-427.  | 2.5  | 28        |
| 334 | The low nuclear grade breast neoplasia family. <i>Diagnostic Histopathology</i> , 2012, 18, 124-132.  | 0.4  | 10        |
| 335 | The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. <i>Nature</i> , 2012, 486, 346-352.  | 27.8 | 4,708     |
| 336 | The prognostic significance of lymphovascular invasion in invasive breast carcinoma. <i>Cancer</i> , 2012, 118, 3670-3680.  | 4.1  | 197       |
| 337 | Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 519-529.   | 2.5  | 25        |
| 338 | EpCAM expression is an indicator of recurrence in basal-like breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 575-582.   | 2.5  | 22        |
| 339 | A CD44 <sup>hi</sup> /CD24 <sup>+</sup> phenotype is a poor prognostic marker in early invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 979-995.  | 2.5  | 89        |
| 340 | Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 171-180. | 2.5  | 21        |
| 341 | A review of the biological and clinical characteristics of luminal-like oestrogen receptor positive breast cancer. <i>Histopathology</i> , 2012, 60, 854-863.   | 2.9  | 22        |
| 342 | Re-audit of revised method for assessing the mitotic component of histological grade in needle core biopsies of invasive carcinoma of the breast. <i>Histopathology</i> , 2012, 60, 1166-1167.                                | 2.9  | 3         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 343 | Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. <i>Breast Cancer Research</i> , 2012, 14, R3.  | 5.0 | 105       |
| 344 | Invasive Ductal Carcinoma of No Special Type and Histologic Grade. , 2012, , 429-445.  |     | 1         |
| 345 | Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. <i>Modern Pathology</i> , 2011, 24, 157-167.   | 5.5 | 545       |
| 346 | Modern Classification of Breast Cancer. <i>Advances in Anatomic Pathology</i> , 2011, 18, 255-267.   | 4.3 | 64        |
| 347 | Encapsulated Papillary Carcinoma of the Breast. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1093-1103.   | 3.7 | 122       |
| 348 | Outcome of breast lesions diagnosed as lesion of uncertain malignant potential (B3) or suspicious of malignancy (B4) on needle core biopsy, including detailed review of epithelial atypia. <i>Histopathology</i> , 2011, 58, 626-632.   | 2.9 | 58        |
| 349 | Histological grade of invasive carcinoma of the breast assessed on needle core biopsy - modifications to mitotic count assessment to improve agreement with surgical specimens. <i>Histopathology</i> , 2011, 59, 543-548.               | 2.9 | 28        |
| 350 | Metastatic Triple-negative Breast Cancer. <i>Clinical Oncology</i> , 2011, 23, 587-600.  | 1.4 | 95        |
| 351 | Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 407-416.  | 2.5 | 52        |
| 352 | MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 591-599.  | 2.5 | 93        |
| 353 | RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 315-326.                                      | 2.5 | 41        |
| 354 | FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 11-21.   | 2.5 | 69        |
| 355 | Metaplastic breast carcinoma: tumour histogenesis or dedifferentiation?. <i>Journal of Pathology</i> , 2011, 224, 434-437.   | 4.5 | 43        |
| 356 | The impact of using defined criteria for adequacy of fine needle aspiration cytology of the thyroid in routine practice. <i>Diagnostic Cytopathology</i> , 2011, 39, 81-86.  | 1.0 | 23        |
| 357 | Characterization and outcome of breast needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. <i>International Journal of Cancer</i> , 2011, 129, 1417-1424. | 5.1 | 91        |
| 358 | Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. <i>Modern Pathology</i> , 2011, 24, 774-785.   | 5.5 | 114       |
| 359 | Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast. <i>Journal of Clinical Pathology</i> , 2011, 64, 995-1000.   | 2.0 | 44        |
| 360 | Clinical and Biological Significance of E-cadherin Protein Expression in Invasive Lobular Carcinoma of the Breast. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1472-1479.  | 3.7 | 132       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 361 | Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 283-293.   | 2.5 | 193       |
| 362 | A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 83-93.   | 2.5 | 62        |
| 363 | The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 603-612.  | 2.5 | 83        |
| 364 | The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 41-51.  | 2.5 | 47        |
| 365 | PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 45-53.   | 2.5 | 73        |
| 366 | Combinatorial biomarker expression in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 293-308.  | 2.5 | 176       |
| 367 | Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer. <i>International Journal of Cancer</i> , 2010, 126, 1761-1769.   | 5.1 | 36        |
| 368 | The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. <i>Diagnostic Cytopathology</i> , 2010, 38, 874-879.   | 1.0 | 69        |
| 369 | A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients. <i>Computers in Biology and Medicine</i> , 2010, 40, 318-330.   | 7.0 | 55        |
| 370 | Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation. <i>Histopathology</i> , 2010, 57, 212-219.  | 2.9 | 44        |
| 371 | Cytological assessment of conventional transbronchial fine needle aspiration of lymph nodes. <i>Cytopathology</i> , 2010, 21, 27-34.  | 0.7 | 16        |
| 372 | Topo2 $\beta$ protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer. <i>British Journal of Cancer</i> , 2010, 103, 1794-1800.                                   | 6.4 | 23        |
| 373 | Evaluation of touch preparation cytology during frozen-section diagnoses of pulmonary lesions. <i>Journal of Clinical Pathology</i> , 2010, 63, 675-677.  | 2.0 | 11        |
| 374 | Tubular Carcinoma of the Breast: Further Evidence to Support Its Excellent Prognosis. <i>Journal of Clinical Oncology</i> , 2010, 28, 99-104.   | 1.6 | 154       |
| 375 | Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies. <i>PLoS Medicine</i> , 2010, 7, e1000279. | 8.4 | 764       |
| 376 | Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast. <i>Modern Pathology</i> , 2010, 23, 1357-1363.   | 5.5 | 51        |
| 377 | Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic fatty liver disease. <i>Journal of Clinical Pathology</i> , 2010, 63, 790-795.  | 2.0 | 51        |
| 378 | Screen-detected malignant breast lesions diagnosed following benign (B2) or normal (B1) needle core biopsy diagnoses. <i>European Journal of Cancer</i> , 2010, 46, 1835-1840.  | 2.8 | 7         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 379 | Lobular breast carcinoma and its variants. <i>Seminars in Diagnostic Pathology</i> , 2010, 27, 49-61.  | 1.5 | 122       |
| 380 | Breast cancer prognostic classification in the molecular era: the role of histological grade. <i>Breast Cancer Research</i> , 2010, 12, 207.   | 5.0 | 650       |
| 381 | Influence of E-cadherin Expression on the Mammographic Appearance of Invasive Nonlobular Breast Carcinoma Detected at Screening. <i>Radiology</i> , 2009, 253, 51-55.  | 7.3 | 12        |
| 382 | Global Histone Modifications in Breast Cancer Correlate with Tumor Phenotypes, Prognostic Factors, and Patient Outcome. <i>Cancer Research</i> , 2009, 69, 3802-3809.  | 0.9 | 417       |
| 383 | The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 243-250.  | 2.5 | 47        |
| 384 | Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 199-204.   | 2.5 | 76        |
| 385 | Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 59-66.  | 2.5 | 52        |
| 386 | Patho-biological aspects of basal-like breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 411-422.  | 2.5 | 72        |
| 387 | The expression of ER $\alpha$ , ER $\beta$ and PR in lobular carcinoma <i>in situ</i> of the breast determined using laser microdissection and real-time PCR. <i>Histopathology</i> , 2009, 54, 419-427.   | 2.9 | 13        |
| 388 | Sonographic correlations with the new molecular classification of invasive breast cancer. <i>European Radiology</i> , 2009, 19, 2342-2348.   | 4.5 | 52        |
| 389 | Will MRI screening deliver the expected survival advantage in BRCA 1 carriers?. <i>Clinical Radiology</i> , 2009, 64, 1045-1047.   | 1.1 | 2         |
| 390 | Screen-detected breast lesions with malignant needle core biopsy diagnoses and no malignancy identified in subsequent surgical excision specimens (potential false-positive diagnosis). <i>European Journal of Cancer</i> , 2009, 45, 1162-1167. | 2.8 | 21        |
| 391 | Triple-negative/basal-like breast cancer: review. <i>Pathology</i> , 2009, 41, 40-47.  | 0.6 | 226       |
| 392 | Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification. <i>Breast Cancer Research</i> , 2009, 11, R90.   | 5.0 | 42        |
| 393 | Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes. <i>Clinical Cancer Research</i> , 2009, 15, 2302-2310.  | 7.0 | 422       |
| 394 | Basal-like Breast Carcinoma: From Expression Profiling to Routine Practice. <i>Archives of Pathology and Laboratory Medicine</i> , 2009, 133, 860-868.   | 2.5 | 66        |
| 395 | Expression profiling technology: its contribution to our understanding of breast cancer. <i>Histopathology</i> , 2008, 52, 67-81.  | 2.9 | 42        |
| 396 | The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 427-437.                           | 2.5 | 57        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 397 | Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 121-127.                             | 2.5 | 122       |
| 398 | Letter to the Editor. <i>Modern Pathology</i> , 2008, 21, 1060-1061.  | 5.5 | 11        |
| 399 | Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. <i>British Journal of Cancer</i> , 2008, 99, 327-334.                                 | 6.4 | 139       |
| 400 | Predictive value of needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. <i>Histopathology</i> , 2008, 53, 650-657. | 2.9 | 131       |
| 401 | Vacuum-assisted excision of breast lesions of uncertain malignant potential (B3) – an alternative to surgery in selected cases. <i>Breast</i> , 2008, 17, 546-549.                                | 2.2 | 41        |
| 402 | Expression of BRCA1 protein in breast cancer and its prognostic significance. <i>Human Pathology</i> , 2008, 39, 857-865.   | 2.0 | 133       |
| 403 | Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes. <i>European Journal of Cancer</i> , 2008, 44, 73-83.   | 2.8 | 206       |
| 404 | Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. <i>European Journal of Cancer</i> , 2008, 44, 1541-1551.   | 2.8 | 79        |
| 405 | Audit of performance of needle core biopsy diagnoses of screen detected breast lesions. <i>European Journal of Cancer</i> , 2008, 44, 2580-2586.  | 2.8 | 38        |
| 406 | The mammographic correlations of a new immunohistochemical classification of invasive breast cancer. <i>Clinical Radiology</i> , 2008, 63, 1228-1235.   | 1.1 | 32        |
| 407 | Basal-Like Breast Cancer: A Critical Review. <i>Journal of Clinical Oncology</i> , 2008, 26, 2568-2581.   | 1.6 | 784       |
| 408 | Breast Carcinoma with Basal Phenotype: Mammographic Findings. <i>American Journal of Roentgenology</i> , 2008, 191, 346-351.  | 2.2 | 41        |
| 409 | Prognostic Significance of Nottingham Histologic Grade in Invasive Breast Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3153-3158.   | 1.6 | 462       |
| 410 | Are Triple-Negative and Basal-Like Breast Cancer Synonymous?. <i>Clinical Cancer Research</i> , 2008, 14, 618-618.  | 7.0 | 45        |
| 411 | Impact of Basal-Like Breast Carcinoma Determination for a More Specific Therapy. <i>Pathobiology</i> , 2008, 75, 95-103.  | 3.8 | 31        |
| 412 | Biologic and Clinical Characteristics of Breast Cancer With Single Hormone Receptor – Positive Phenotype. <i>Journal of Clinical Oncology</i> , 2007, 25, 4772-4778.                              | 1.6 | 261       |
| 413 | Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up. <i>Journal of Medical Screening</i> , 2007, 14, 210-214.                  | 2.3 | 26        |
| 414 | Are triple-negative tumours and basal-like breast cancer synonymous?. <i>Breast Cancer Research</i> , 2007, 9, 404; author reply 405.   | 5.0 | 98        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 415 | The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. <i>International Journal of Cancer</i> , 2007, 120, 1311-1317.   | 5.1 | 40        |
| 416 | Prognostic markers in triple-negative breast cancer. <i>Cancer</i> , 2007, 109, 25-32.   | 4.1 | 1,091     |
| 417 | Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. <i>Histopathology</i> , 2007, 50, 434-438.   | 2.9 | 152       |
| 418 | Gigantic recurrent abdominal desmoid tumour: a case report. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , 2007, 11, 193-197.  | 2.0 | 9         |
| 419 | Are triple negative tumours and basal-like breast cancer synonymous?. <i>Breast Cancer Research</i> , 2007, 9, R80.  | 5.0 | 6         |
| 420 | Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. <i>European Journal of Cancer</i> , 2006, 42, 3149-3156.  | 2.8 | 179       |
| 421 | Chromosome 16 tumor-suppressor genes in breast cancer. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 527-535.  | 2.8 | 75        |
| 422 | E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. <i>Histopathology</i> , 2005, 46, 685-693.  | 2.9 | 150       |
| 423 | Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. <i>Modern Pathology</i> , 2005, 18, 26-35.   | 5.5 | 232       |
| 424 | Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. <i>Modern Pathology</i> , 2005, 18, 1295-1304.  | 5.5 | 305       |
| 425 | High-resolution analysis of 16q22.1 in breast carcinoma using DNA amplifiable probes (multiplex) Tj ETQq1 1 0.784314 rgBT /Overloc<br>Cancer, 2005, 114, 720-729.  | 5.1 | 22        |
| 426 | High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. <i>International Journal of Cancer</i> , 2005, 116, 340-350. | 5.1 | 500       |
| 427 | Expression of the transcription factor CTCF in invasive breast cancer: a candidate gene located at 16q22.1. <i>British Journal of Cancer</i> , 2004, 91, 1591-1596.  | 6.4 | 32        |
| 428 | Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis. <i>Journal of Pathology</i> , 2004, 203, 754-761.   | 4.5 | 37        |